Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Tuesday that it has agreed to purchase V-Wave, a privately held medical device company, for an upfront payment of USD600m.
The deal could be worth up to an additional USD1.1bn in regulatory and commercial milestone payments.
V-Wave specialises in heart failure treatments, particularly its Ventura Interatrial Shunt (IAS) device. The IAS is designed to reduce the strain on the heart by redirecting blood flow. This minimally invasive procedure aims to bridge the gap between medical treatments and more invasive options like heart transplants.
The acquisition strengthens Johnson & Johnson MedTech's position in cardiovascular care and expands its reach in high-growth markets. The deal is expected to close before the end of 2024.
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Rona Therapeutics granted Chinese approval of IND application for hypertension drug candidate RN1871
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation